4976-72-1

Downstream Products

• 82362-12-7 Z-Phe-Met-OBu^t 
• 116823-58-6 Nps-Asn(Mbh)-Met-OBu^t 
• 58569-55-4 met-enkephalin 
• 82362-13-8 H-Phe-Met-OBu^t 
• 82362-15-0 H-Gly-Phe-Met-OBu^t 
• 82362-14-9 Z-Gly-Phe-Met-OBu^t 
• 82362-16-1 Boc-Tyr-Gly-Gly-Phe-Met-OBu^t 
• 223759-30-6 tert-butyl (2S)-2-{2-(4-fluorophenyl)-4-[2-(imidazol-1-yl)-1-(4-fluorophenyl)ethoxymethyl]benzoylamino}-4-methylsulfanylbutyrate 
• 223759-63-5 tert-butyl (2S)-2-{2-(4-fluorophenethyl)-4-[1-(4-fluorophenyl)-2-(imidazol-1-yl)ethoxymethyl]benzoylamino}-4-methylsulfanylbutyrate 
• 223759-95-3 tert-Butyl (2S)-2-{5-[1-(4-fluorophenyl)-2-(imidazol-1-yl)ethoxy]-2-(4-fluorophenethyl)benzoylamino}-4-methylsulfanylbutyrate 
• 223760-14-3 tert-butyl (2S)-2-{2-(4-fluorophenethyl)-5-[1-(4-fluorophenyl)-2-(1-methylimidazol-5-yl)ethoxy]benzoylamino}-4-methylsulfanylbutyrate 
• 223760-43-8 tert-butyl (2S)-2-{2-(4-fluorophenyl)-4-[1-(4-fluorophenyl)-2-(1-methylimidazol-5-yl)ethoxymethyl]benzoylamino}-4-methylsulfanylbutyrate 
• 1025813-30-2 tert-Butyl (2S)-2-{5-[(E)-3-(Imidazol-1-yl)prop-1-en-1-yl]-2-(4-fluorophenethyl)benzamido}-4-methylsulfanylbutyrate 
• 1147135-63-4 C₁₉H₂₈N₂O₆S₂ 

Relevant academic research and scientific papers

High molecular weight polymer-based prodrugs

The present invention is directed compositions of the formula: STR1 wherein: D is a residue of biologically active moiety; X is an electron withdrawing group; Y and Y' are independently O or S; (n) is zero (0) or a positive integer, preferably from 1 to about 12; wherein: R1 and R2 are independently selected from the group consisting of H, C1-6 alkyls, aryls, substituted aryls, aralkyls, heteroalkyls, substituted heteroalkyls and substituted C1-6 alkyls; wherein: R3 is a substantially non-antigenic polymer, C1-12 straight or branched alkyl or substituted allyl, C5-8 cycloalkyl or substituted cycloalkyl, carboxyalkyl, carboalkoxy alkyl, dialkylaminoalkyl, phenylalkyl, phenylaryl or STR2 wherein: R4 and R5 are independently selected from the group consisting of H, C1-6 alkyls, aryls, substituted aryls, aralkyls, heteroalkyls, substituted heteroalkyls, and substituted C1-6 alkyls or jointly form a cyclic C5 -C7 ring. In preferred embodiments, the prodrugs contain a polyethylene glycol having a molecular weight of at least about 20,000.

High molecular weight polymer-based prodrugs

The present invention is directed compositions of the formula: STR1 wherein: D is a biologically active moiety; X is an electron withdrawing group; Y and Y' are independently O or S; R1 is selected from the group consisting of H, C1-6 alkyls, aryls, substituted aryls, aralkyls, heteroalkyls, substituted heteroalkyls and substituted C1-6 alkyls; (n) is an integer from 1 to about 12; and R2 is a polyalkylene oxide. In preferred embodiments, the prodrugs contain a polyethylene glycol having a molecular weight of at least about 20,000.